Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 | P05230 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | CXCL10 | P02778 | 1/20 | 0.34 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.34 |
| ▸ | CCL2 | P13500 | 1/20 | 0.34 |
| ▸ | CCL5 | P13501 | 1/20 | 0.34 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 2/20 | 0.33 |
| ▸ | BDNF | P23560 | 3/20 | 0.32 |
| ▸ | PTN | P21246 | 2/20 | 0.32 |
| ▸ | MDK | P21741 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19221012 | 1.00 | FGF1 (0.37) | FGF1AKT1CXCL10CXCL8CCL2 | |
| SCHEMBL19220864 | 0.94 | AKT1 (0.39) | FGF1AKT1 | |
| SCHEMBL14212353 | 0.94 | AKT1 (0.39) | FGF1AKT1 | |
| SCHEMBL14212363 | 0.94 | AKT1 (0.39) | FGF1AKT1 | |
| SCHEMBL11994265 | 0.94 | AKT1 (0.39) | FGF1AKT1 | |
| SCHEMBL23710806 | 0.94 | AKT1 (0.39) | FGF1AKT1 | |
| SCHEMBL19220861 | 0.94 | AKT1 (0.39) | FGF1AKT1 | |
| SCHEMBL14212365 | 0.94 | AKT1 (0.39) | FGF1AKT1 | |
| SCHEMBL19221011 | 0.94 | AKT1 (0.39) | FGF1AKT1 | |
| SCHEMBL19220857 | 0.94 | AKT1 (0.39) | FGF1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130084-A1 | MODIFIED ALGINATES FOR CELL ENCAPSULATION AND CELL THERAPY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-04-27 | — | — | US | disclosed |
| US-20180092850-A1 | HYDROGEL ENCAPSULATED CELLS AND ANTI-INFLAMMATORY DRUGS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2018-04-05 | — | — | US | disclosed |
| US-9867781-B2 | Hydrogel encapsulated cells and anti-inflammatory drugs | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170239397-A1 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS | UNITED STATES GOVERNMENT | 2017-08-24 | — | — | US | disclosed |
| US-20170239190-A1 | MODIFIED ALGINATES FOR CELL ENCAPSULATION AND CELL THERAPY | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2017-08-24 | — | — | US | disclosed |
| US-20170226232-A1 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2017-08-10 | — | — | US | disclosed |
| US-20170095514-A1 | Multi-Layer Hydrogel Capsules for Encapsulation of Cells and Cell Aggregates | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-06 | — | — | US | disclosed |
| US-9555007-B2 | Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160324793-A1 | MODIFIED ALGINATES FOR CELL ENCAPSULATION AND CELL THERAPY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2016-11-10 | — | — | US | disclosed |
| US-9422373-B2 | Modified alginates for cell encapsulation and cell therapy | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160030360-A1 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS | US ARMY, SECRETARY OF THE ARMY | 2016-02-04 | — | — | US | disclosed |
| US-20160030359-A1 | Multi-Layer Hydrogel Capsules for Encapsulation of Cells and Cell Aggregates | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-02-04 | — | — | US | disclosed |
| US-20140271843-A1 | Multi-Layer Hydrogel Capsules for Encapsulation of Cells and Cell Aggregates | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-09-18 | — | — | US | disclosed |
| US-20120308650-A1 | MODIFIED ALGINATES FOR CELL ENCAPSULATION AND CELL THERAPY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2012-12-06 | — | — | US | disclosed |
| US-20120213708-A1 | HYDROGEL ENCAPSULATED CELLS AND ANTI-INFLAMMATORY DRUGS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226232-A1 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS | ALG1, FIBP, COL2A1 | FGF1 386/4885AKT1 4642/4885CXCL10 421/4885 |
| US-20170239397-A1 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS | ALG1, FIBP, COL2A1 | FGF1 386/4885AKT1 4642/4885CXCL10 421/4885 |
| US-20160324793-A1 | MODIFIED ALGINATES FOR CELL ENCAPSULATION AND CELL THERAPY | ALG1, CD44, CD47 | FGF1 713/4885AKT1 4683/4885CXCL10 1158/4885 |
| US-20120308650-A1 | MODIFIED ALGINATES FOR CELL ENCAPSULATION AND CELL THERAPY | ALG1, CD44, CD47 | FGF1 713/4885AKT1 4683/4885CXCL10 1158/4885 |
| US-20160030359-A1 | Multi-Layer Hydrogel Capsules for Encapsulation of Cells and Cell Aggregates | FIBP, PLOD3, CD44 | FGF1 52/4885AKT1 4124/4885CXCL10 198/4885 |
| US-20170095514-A1 | Multi-Layer Hydrogel Capsules for Encapsulation of Cells and Cell Aggregates | CD44, PLOD3, FIBP | FGF1 89/4885AKT1 4356/4885CXCL10 267/4885 |
| US-20180092850-A1 | HYDROGEL ENCAPSULATED CELLS AND ANTI-INFLAMMATORY DRUGS | MIF, HPGDS, TNF | FGF1 49/4885AKT1 3838/4885CXCL10 25/4885 |
| US-20120213708-A1 | HYDROGEL ENCAPSULATED CELLS AND ANTI-INFLAMMATORY DRUGS | MIF, HPGDS, TNF | FGF1 49/4885AKT1 3838/4885CXCL10 25/4885 |
| US-20230130084-A1 | MODIFIED ALGINATES FOR CELL ENCAPSULATION AND CELL THERAPY | ALG1, CD44, CD47 | FGF1 713/4885AKT1 4683/4885CXCL10 1158/4885 |
| US-20170239190-A1 | MODIFIED ALGINATES FOR CELL ENCAPSULATION AND CELL THERAPY | ALG1, CD44, CD47 | FGF1 713/4885AKT1 4683/4885CXCL10 1158/4885 |
| US-20140271843-A1 | Multi-Layer Hydrogel Capsules for Encapsulation of Cells and Cell Aggregates | CD44, PLOD3, FIBP | FGF1 89/4885AKT1 4356/4885CXCL10 267/4885 |
| US-20160030360-A1 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS | ALG1, FIBP, COL2A1 | FGF1 386/4885AKT1 4642/4885CXCL10 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.